Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.

Horby P., Staplin N., Haynes R., Landray M.

DOI

10.1016/s0140-6736(21)01422-7

Type

Working paper

Publication Date

07/2021

Volume

398

Addresses

Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK. Electronic address: peter.horby@ndm.ox.ac.uk.

Keywords

Humans, Antibodies, Monoclonal, Humanized, COVID-19, SARS-CoV-2

Permalink Original publication